FLIPI24
FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma.
About
The FLIPI24 calculates the probability (%) of event (progression, re-treatment, transformation, or death) within the first two years after starting frontline immunochemotherapy. The model assumes CD20 antibody plus CHOP or bendamustine based chemotherapy with a 50% likelihood of CD20 antibody maintenance. The model data are from the FLIPI24 Consortium, which is comprised of patient data from 10 international cohorts.
References
MJ Maurer et al,
By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.